Skip to content
Screener

D&A at other companies

Johnson & Johnson logo
Johnson & JohnsonJNJ
$1.96B+0.8%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$123.7M-8.4%
Sight Sciences, Inc. logo
Sight Sciences, Inc.SGHT
$94K-24.8%
Schering-Plough logo
Schering-PloughSGP
$153K+126%
Bausch + Lomb logo
Bausch + LombBLCO
$102M-4.7%
Ocular Therapeutix logo
Ocular TherapeutixOCUL
$1.28M+30.8%

Segments

By geography

See full
US$8.99M+6.9%

Other financials

Income statement

See full
Revenue$185.6M+49.5%
Gross profit$151.6M+55.9%
Operating income-$17.3M+23.9%
Net income-$18.4M+6.5%
EPS (diluted)-$0.31+8.8%

Balance sheet

See full
Cash & equivalents$114.5M+13.6%
Total debt$105.9M-1.4%
Total equity$682.5M-10.8%
Total assets$920.5M-6.7%

Cash flow

See full
Operating cash flow$14.8M
CapEx$2.7M+132%
Free cash flow-$16.5M+19.4%

Valuation

See full
Market cap$10.09B+98.7%
Enterprise value$10.08B+98.3%
P/S16.5×+4.7×

Profitability

See full
Gross margin61%-15.4pp
Operating margin-31.6%+22.2pp
Net margin-30.7%+23.3pp
FCF margin-13.2%-3.9pp

Returns & leverage

See full
Return on equity-26%-11,301pp
Debt / equity0.2×0.0×
Current ratio-0.5×

Where this comes from

Reported directly by Glaukos in its filing.

Tagged under the XBRL concept us-gaap:Depreciation.

The source filing: Glaukos’s 10-Q, filed July 29, 2026.

Filed
Jul 29, 2026, 5:06 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-324201
Line itemSix Months Ended June 30, 2026Six Months Ended June 30, 2025
Operating Activities
Net loss$(38,160)$(37,803)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Depreciation5,9025,376
Amortization of intangible assets14,76511,420
Amortization of right-of-use lease assets2,3572,133
Deferred income tax benefit-(18)
Loss on disposal of fixed assets24611

Item 1. Financial Statements

FAQ

What is Glaukos's D&A?
Glaukos (GKOS) reported D&A of $2.99M in Q2 2026.
How has Glaukos's D&A changed year-over-year?
Glaukos's D&A increased by 9.8% year-over-year, from $2.73M to $2.99M.
What is the long-term trend for Glaukos's D&A?
Over 4 years (2021 to 2025), Glaukos's D&A has grown at a -22.0% compound annual growth rate (CAGR), from $29.66M to $10.97M.
What does D&A mean?
Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.

Ask your AI about Glaukos's d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude